← Back
Data updated: Mar 10, 2026
PHATHOM
Infectious DiseaseCardiovascularDermatology
PHATHOM is a pharmaceutical company focused on Infectious Disease, Cardiovascular, Dermatology. Key products include VOQUEZNA TRIPLE PAK.
2022
Since
3
Drugs
-
Trials
11
Approved (2yr)
Key Drugs
Recent Activity
VOQUEZNA 2025-11-06
Labeling
VOQUEZNA TRIPLE PAK 2025-10-31
Labeling
VOQUEZNA DUAL PAK 2025-10-31
Labeling
VOQUEZNA TRIPLE PAK 2025-06-12
Labeling
VOQUEZNA DUAL PAK 2025-06-12
Labeling
VOQUEZNA TRIPLE PAK 2024-07-31
Labeling
VOQUEZNA DUAL PAK 2024-07-31
Labeling
VOQUEZNA 2024-07-17
Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
VOQUEZNA 2024-07-17
Labeling
VOQUEZNA TRIPLE PAK 2024-05-01
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 55%
3 drugs Phase 3: 1 Phase 1: 1
Cardiovascular 31%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1
Dermatology 14%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology, Cardiovascular
COSETTE other
Cardiovascular, Dermatology, Infectious Disease
BAUSCH AND LOMB specialty
Cardiovascular, Infectious Disease, Dermatology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Cardiovascular
Active (3)
Discontinued (0)
Company Info
- First Approval
- 2022-05-03
- Latest
- 2025-11-06
- Applications
- 3